Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose psilocybin for pain in fibromyalgia
NL-OMON59453Phase 2Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of psilocybin in fibromyalgia (FM) (3 arms), sponsored by Maastricht University. Primary endpoints: Analgesic effect on pain perception, Pressure Pain Threshold and 2 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NL-OMON59453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59453.